Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb:79:103874.
doi: 10.1016/j.breast.2025.103874. Epub 2025 Jan 2.

Genomic characterization and molecular predictive biomarkers for chemotherapy in patients with metastatic triple-negative breast cancer treated in a real-world setting

Erik Olsson  1 , Henrik Lindman  2 , Evangelos Digkas  3 , Viktoria Thurfjell  4 , Haidar Mir Ali  5 , Ute Krüger  6 , Anna-Karin Wennstig  7 , Marie Sundqvist  8 , Antonios Valachis  9
Affiliations

Genomic characterization and molecular predictive biomarkers for chemotherapy in patients with metastatic triple-negative breast cancer treated in a real-world setting

Erik Olsson et al. Breast. 2025 Feb.

Abstract

Purpose: We aimed to characterize genomic alterations with potential prognostic or predictive significance in patients with metastatic triple-negative breast cancer (mTNBC) treated with chemotherapy in a real-world setting.

Patients and methods: Next-generation sequencing with FoundationOne® CDx was conducted primarily on primary tumor tissue from 112 consecutive patients with mTNBC. Genomic alterations were subdivided into canonical oncogenic pathways and noted for their involvement in homologous recombination deficiency (HRD). Altered genes and pathways were correlated with overall survival (OS) and evaluated regarding their association with real-world progression-free survival (rwPFS) in patients treated with different chemotherapy agents. Occurrence of alterations were compared between patients with exceptional response and rapid progression to chemotherapy.

Results: After exclusion due to insufficient tumor tissue or clinical data, material from 97 patients was analyzed. The most frequently altered genes were TP53 (82 %), RAD21 (25 %) and PIK3CA (23 %). Altogether, 26 % of patients had an alteration leading to HRD. None of the analyzed alterations were associated with OS. Variants leading to HRD were associated with a prolonged rwPFS in patients treated with platinum-based chemotherapy in the first line setting (hazard ratio [HR], 0.31 [95 % CI: 0.12-0.84]). Exceptional responders more often exhibited alterations in the MYC and RAS/RTK pathways compared to rapid progressors.

Conclusions: Patients with tumor alterations in HRD-related genes seem to define subgroups that respond favorably to platinum-based chemotherapy. Further research into the genomic landscape of tumors from patients with rapid progression or exceptional response to different treatment strategies can provide insights into mechanisms of resistance and identify predictive biomarkers.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1a
Fig. 1a
Flowchart of the study cohort.
Fig. 1b
Fig. 1b
Flowchart describing the reasons for exclusion from NGS analysis of retrieved tissue samples. FFPE, Formalin-Fixed, Paraffin-Embedded. ∗ Includes samples from both metastatic tissue and local recurrences.
Fig. 2
Fig. 2
The genomic landscape of the 97-patient cohort. Gene alterations are correlated with the corresponding involved oncogenic signaling pathways (to the far right in the figure) and clinical characteristics. Gene alterations with a prevalence of less than 5 % are excluded. All gene alterations that lead to HRD were collected into one group and BRCA1 and BRCA2 mutations were combined into one group (BRCA).
See this image and copyright information in PMC

References

    1. Won K.A., Spruck C. Triple-negative breast cancer therapy: current and future perspectives. Int J Oncol. 2020 Dec;57(6):1245–1261. (Review) - PMC - PubMed
    1. Schmid P., Adams S., Rugo H.S., Schneeweiss A., Barrios C.H., Iwata H., et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018 Nov 29;379(22):2108–2121. - PubMed
    1. Cortes J., Rugo H.S., Cescon D.W., Im S.A., Yusof M.M., Gallardo C., et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N Engl J Med. 2022 Jul 21;387(3):217–226. - PubMed
    1. Robson M., Im S.A., Senkus E., Xu B., Domchek S.M., Masuda N., et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017 Aug 10;377(6):523–533. - PubMed
    1. Litton J.K., Rugo H.S., Ettl J., Hurvitz S.A., Gonçalves A., Lee K.H., et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018 Aug 23;379(8):753–763. - PMC - PubMed

MeSH terms

Substances